Loading..

Geron Corporation (GERN) Report Analysis

Corporate Events

Positive

Geron Corporation(NasdaqGS:GERN) added to Russe...

2022-06-24 00:00:00

Geron Corporation(NasdaqGS:GERN) added to Russell 3000 Growth Index

Positive

Geron Corporation(NasdaqGS:GERN) added to Russe...

2022-06-24 00:00:00

Geron Corporation(NasdaqGS:GERN) added to Russell 2000 Growth Index

Positive

Geron Corporation(NasdaqGS:GERN) added to Russe...

2022-06-24 00:00:00

Geron Corporation(NasdaqGS:GERN) added to Russell Small Cap Comp Growth Index

Positive

Geron Corporation(NasdaqGS:GERN) added to Russe...

2022-06-24 00:00:00

Geron Corporation(NasdaqGS:GERN) added to Russell 2500 Growth Index

Positive

Geron Corporation(NasdaqGS:GERN) added to Russe...

2022-06-24 00:00:00

Geron Corporation(NasdaqGS:GERN) added to Russell 3000E Growth Index

Positive

Geron Corporation(NasdaqGS:GERN) added to Russe...

2022-06-24 00:00:00

Geron Corporation(NasdaqGS:GERN) added to Russell Microcap Growth Index

Negative

Geron Corporation Announces Executive Changes

2022-06-15 21:16:00

Geron Corporation announced that Aleksandra Rizo, M.D., Ph.D., notified Geron Corporation of her decision to resign from her position as Execu...

Negative

Geron Corporation Announces Board Appointment

2022-06-15 20:10:00

Geron Corporation announced the appointment of Faye Feller, M.D., to Executive Vice President and Chief Medical Officer, effective July 9, 202...

Neutral

Geron Corporation Presents at H.C. Wainwright G...

2022-05-17 20:30:00

Geron Corporation Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel,...

Neutral

Geron Corporation to Report Q1, 2022 Results on...

2022-05-02 20:30:00

Geron Corporation announced that they will report Q1, 2022 results After-Market on May 09, 2022

Neutral

Geron Corporation, Q1 2022 Earnings Call, May 09, 2022

2022-05-02 20:30:00

Geron Corporation, Q1 2022 Earnings Call, May 09, 2022

Neutral

Geron Corporation Presents at Needham 21st Annu...

2022-04-06 20:30:00

Geron Corporation Presents at Needham 21st Annual Healthcare Conference, Apr-13-2022 03:45 PM. Speakers: John A. Scarlett, Chairman of the Boa...

Negative

Geron Corporation has filed a Follow-on Equity ...

2022-03-29 00:00:00

Geron Corporation has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Security Name: Pre-Fun...

Negative

Geron Corporation has completed a Follow-on Equ...

2022-03-29 00:00:00

Geron Corporation has completed a Follow-on Equity Offering in the amount of $74.981905 million. Security Name: Common Stock Security Type...

Negative

Certain Pre-funded warrants of Geron Corporatio...

2022-03-29 00:00:00

Certain Pre-funded warrants of Geron Corporation are subject to a Lock-Up Agreement Ending on 28-JUN-2022. These Pre-funded warrants will be u...

Negative

Certain Common Stock of Geron Corporation are s...

2022-03-29 00:00:00

Certain Common Stock of Geron Corporation are subject to a Lock-Up Agreement Ending on 28-JUN-2022. These Common Stock will be under lockup fo...

Negative

Certain Stock Options of Geron Corporation are ...

2022-03-29 00:00:00

Certain Stock Options of Geron Corporation are subject to a Lock-Up Agreement Ending on 28-JUN-2022. These Stock Options will be under lockup ...

Negative

Certain Warrants of Geron Corporation are subje...

2022-03-29 00:00:00

Certain Warrants of Geron Corporation are subject to a Lock-Up Agreement Ending on 28-JUN-2022. These Warrants will be under lockup for 91 day...

Neutral

Geron Corporation - Shareholder/Analyst Call

2022-03-22 21:16:00

Annual Meeting of Stockholders

Neutral

Geron Corporation, Annual General Meeting, May 10, 2022

2022-03-22 21:16:00

Geron Corporation, Annual General Meeting, May 10, 2022, at 16:00 Pacific Standard Time. Agenda: To consider election of the two nominees for ...

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Glo...

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami B...

Neutral

Needham & Company, LLC, Needham 21st Annual Hea...

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Neutral

Geron Corporation Presents at B. Riley Securiti...

2022-01-21 12:30:00

Geron Corporation Presents at B. Riley Securities Oncology Investor Conference 2022, Jan-28-2022 11:00 AM. Speakers: Aleksandra Rizo, Executiv...

Negative

Geron Corporation Announces Executive Changes

2021-12-02 12:30:00

Geron Corporation announced the appointment of Edward Koval as Executive Vice President and Chief Business Officer. In his role at Geron, Mr. ...

Neutral

Geron Corporation Presents at Stifel 2021 Virtu...

2021-11-12 12:30:00

Geron Corporation Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 02:40 PM. Venue: New York, New York, United States. Speak...

Positive

Geron Enters New Innovative Licensing and Acces...

2021-10-25 20:30:00

Geron Corporation announced that imetelstat, the Company’s first in class telomerase inhibitor, has been granted an Innovation Passport, which...

Positive

Geron Announces Completion of Patient Enrollmen...

2021-10-18 11:30:00

Geron Corporation announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class...

Neutral

Geron Corporation - Special Call

2021-10-15 20:05:00

To discuss The unmet medical needs in lower risk myelodysplastic syndromes and refractory myelofibrosis and the disease modification potential...

Positive

Geron Corporation Announces Publication of Anal...

2021-10-11 20:30:00

Geron Corporation announced the publication in the Annals of Hematology of a paper entitled “Favorable Overall Survival with Imetelstat in Rel...

Neutral

Geron Corporation Presents at H.C. Wainwright 2...

2021-09-01 20:30:00

Geron Corporation Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hot...

Neutral

Geron Corporation Presents at Cantor Global Hea...

2021-09-01 20:30:00

Geron Corporation Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 03:20 PM. Venue: New York, United States.

Neutral

Geron Corporation Presents at Baird Global Heal...

2021-08-26 17:20:00

Geron Corporation Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 02:00 PM. Speakers: John A. Scarlett, CEO, President & Chai...

Positive

Geron Corporation Reports Greater Than 90% Enro...

2021-08-16 20:06:00

Geron Corporation reported updates on the IMerge Phase 3 trial in lower risk MDS and financial results for the second quarter ended June 30, 2...

Neutral

Geron Corporation has filed a Shelf Registratio...

2021-08-16 00:00:00

Geron Corporation has filed a Shelf Registration in the amount of $22.326 million. Security Name: Common Stock Securities Offered: 18,300,...

Neutral

Robert W. Baird & Co. Incorporated, Baird Globa...

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Neutral

Geron Corporation, Q2 2021 Earnings Call, Aug 16, 2021

2021-08-05 20:30:00

Geron Corporation, Q2 2021 Earnings Call, Aug 16, 2021

Neutral

Geron Corporation to Report Q2, 2021 Results on...

2021-08-05 20:30:00

Geron Corporation announced that they will report Q2, 2021 results After-Market on Aug 16, 2021

Neutral

Stifel, Nicolaus & Company, Incorporated, Stife...

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New ...

Positive

Geron Corporation(NasdaqGS:GERN) added to Russell 3000 Growth Index

2022-06-24 00:00:00

Geron Corporation(NasdaqGS:GERN) added to Russell 3000 Growth Index

Positive

Geron Corporation(NasdaqGS:GERN) added to Russell 2000 Growth Index

2022-06-24 00:00:00

Geron Corporation(NasdaqGS:GERN) added to Russell 2000 Growth Index

Positive

Geron Corporation(NasdaqGS:GERN) added to Russell Small Cap Comp Growth Index

2022-06-24 00:00:00

Geron Corporation(NasdaqGS:GERN) added to Russell Small Cap Comp Growth Index

Positive

Geron Corporation(NasdaqGS:GERN) added to Russell 2500 Growth Index

2022-06-24 00:00:00

Geron Corporation(NasdaqGS:GERN) added to Russell 2500 Growth Index

Positive

Geron Corporation(NasdaqGS:GERN) added to Russell 3000E Growth Index

2022-06-24 00:00:00

Geron Corporation(NasdaqGS:GERN) added to Russell 3000E Growth Index

Positive

Geron Corporation(NasdaqGS:GERN) added to Russell Microcap Growth Index

2022-06-24 00:00:00

Geron Corporation(NasdaqGS:GERN) added to Russell Microcap Growth Index

Negative

Geron Corporation Announces Executive Changes

2022-06-15 21:16:00

Geron Corporation announced that Aleksandra Rizo, M.D., Ph.D., notified Geron Corporation of her decision to resign from her position as Executive Vice President and Chief Medical Officer of the Company, with her last day of employment being July 8, 2022. Dr. Rizo resigned in order to accept a leadership position with a privately-held discovery and preclinical-stage platform biotechnology company; not because of her assessment of any clinical data related to the ongoing Phase 3 clinical trials or any disagreement relating to the Company’s management, board of directors, operations, financial statements, internal controls, policies or practices. Accordingly, Dr. Rizo will continue as a consultant to the Company as Senior Medical and Regulatory Advisor to the Company’s development and regulatory teams and will assist in the assessment of data for top-line results from the ongoing IMerge Phase 3 trial in lower risk myelodysplastic syndromes and, assuming supportive top-line results, through the planned FDA New Drug Application submission and acceptance process for imetelstat in lower risk MDS. Effective as of July 9, 2022, Faye Feller, M.D., will assume the duties and responsibilities of Executive Vice President and Chief Medical Officer of the Company. Dr. Feller, age 40, joined Geron in 2019 as Vice President, Clinical Development and has provided hematology-oncology medical expertise to the clinical science and operations teams in the execution and monitoring of clinical trials. In addition, she has served as the primary medical point of contact between Geron and other medically qualified healthcare professionals, including clinical investigators, prescribers, medical professionals at payer organizations and regulatory authorities. Prior to Geron, Dr. Feller was Senior Director at Janssen Research and Development, LLC and both a Compound Lead and Study Responsible Physician for multiple clinical trials of early and late-stage development assets at Janssen, including the IMbark Phase 2 clinical trial of imetelstat where she was responsible for protocol writing, regulatory interactions, medical monitoring, study results interpretation and preparation of abstracts and final study reports. Prior to Janssen, Dr. Feller was an attending physician and instructor in the leukemia department of Memorial Sloan Kettering Cancer Center in New York. Dr. Feller holds a B.A. from New York University and an M.D. from Mount Sinai School of Medicine. She completed her residency in internal medicine at Mount Sinai Hospital and her fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.

Negative

Geron Corporation Announces Board Appointment

2022-06-15 20:10:00

Geron Corporation announced the appointment of Faye Feller, M.D., to Executive Vice President and Chief Medical Officer, effective July 9, 2022. Dr. Feller will succeed Dr. Aleksandra Rizo, Gerons current Chief Medical Officer, who will transition to a consultant role to the Company, as Senior Medical and Regulatory Advisor. Outside of Geron, Dr. Rizo has accepted a leadership position with a privately held discovery and preclinical-stage platform biotechnology company. Dr. Feller has been instrumental in the design, execution and management of the imetelstat development program for the past seven years, starting when she served as a medical leader in Janssen’s hematology program. She has continued her work on imetelstat since 2019, as Gerons Vice President of Clinical Development reporting to Dr. Rizo. When Dr. Feller becomes Chief Medical Officer, Dr. Rizo will transition to the consultant role, where she will continue to be involved in key imetelstat development and regulatory activities. These include assessment of data for top-line results from the ongoing IMerge Phase 3 trial in lower risk myelodysplastic syndromes (MDS) and, assuming supportive top-line results, through the planned FDA New Drug Application submission and acceptance process for imetelstat in lower risk MDS. Prior to joining Geron, Dr. Feller was Senior Director at Janssen Research and Development, LLC (Janssen) and both a Compound Lead and Study Responsible Physician for multiple clinical trials of early and late-stage development assets at Janssen, including the IMbark Phase 2 clinical trial of imetelstat. Prior to Janssen, Dr. Feller was an attending physician in the leukemia department of Memorial Sloan Kettering Cancer Center in New York. She received a B.A. from New York University and an M.D. from Mount Sinai School of Medicine. She completed her residency in internal medicine at Mount Sinai Hospital and her fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.

Neutral

Geron Corporation Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM

2022-05-17 20:30:00

Geron Corporation Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States. Speakers: John A. Scarlett, Chairman of the Board, President & CEO.

Neutral

Geron Corporation to Report Q1, 2022 Results on May 09, 2022

2022-05-02 20:30:00

Geron Corporation announced that they will report Q1, 2022 results After-Market on May 09, 2022

Neutral

Geron Corporation, Q1 2022 Earnings Call, May 09, 2022

2022-05-02 20:30:00

Geron Corporation, Q1 2022 Earnings Call, May 09, 2022

Neutral

Geron Corporation Presents at Needham 21st Annual Healthcare Conference, Apr-13-2022 03:45 PM

2022-04-06 20:30:00

Geron Corporation Presents at Needham 21st Annual Healthcare Conference, Apr-13-2022 03:45 PM. Speakers: John A. Scarlett, Chairman of the Board, President & CEO.

Negative

Geron Corporation has filed a Follow-on Equity Offering.

2022-03-29 00:00:00

Geron Corporation has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Security Name: Pre-Funded Warrants Security Type: Equity Warrant Security Name: Warrants Security Type: Equity Warrant

Negative

Geron Corporation has completed a Follow-on Equity Offering in the amount of $74.981905 million.

2022-03-29 00:00:00

Geron Corporation has completed a Follow-on Equity Offering in the amount of $74.981905 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 53,333,334 Price\Range: $1.05 Discount Per Security: $0.063 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 18,095,238 Price\Range: $1.049 Discount Per Security: $0.06294 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 35,714,286

Negative

Certain Pre-funded warrants of Geron Corporation are subject to a Lock-Up Agreement Ending on 28-JUN-2022.

2022-03-29 00:00:00

Certain Pre-funded warrants of Geron Corporation are subject to a Lock-Up Agreement Ending on 28-JUN-2022. These Pre-funded warrants will be under lockup for 91 days starting from 29-MAR-2022 to 28-JUN-2022. Details: All of the officers and directors have agreed, subject to certain exceptions, not to (1) directly or indirectly (i) offer, pledge, sell, or contract to sell; (ii) sell any option or contract to purchase or purchase any option or contract to sell; (iii) grant any option, right or warrant for the sale; or (iv) dispose of or transfer any shares; or (2) otherwise enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of shares of our common stock or any securities convertible into or exchangeable or exercisable for shares of our common stock, whether now owned or acquired hereafter, without the prior written consent of Stifel, Nicolaus & Company, Incorporated, for a period of 90 days after the date of this prospectus supplement.

Negative

Certain Common Stock of Geron Corporation are subject to a Lock-Up Agreement Ending on 28-JUN-2022.

2022-03-29 00:00:00

Certain Common Stock of Geron Corporation are subject to a Lock-Up Agreement Ending on 28-JUN-2022. These Common Stock will be under lockup for 91 days starting from 29-MAR-2022 to 28-JUN-2022. Details: All of the officers and directors have agreed, subject to certain exceptions, not to (1) directly or indirectly (i) offer, pledge, sell, or contract to sell; (ii) sell any option or contract to purchase or purchase any option or contract to sell; (iii) grant any option, right or warrant for the sale; or (iv) dispose of or transfer any shares; or (2) otherwise enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of shares of our common stock or any securities convertible into or exchangeable or exercisable for shares of our common stock, whether now owned or acquired hereafter, without the prior written consent of Stifel, Nicolaus & Company, Incorporated, for a period of 90 days after the date of this prospectus supplement.

Negative

Certain Stock Options of Geron Corporation are subject to a Lock-Up Agreement Ending on 28-JUN-2022.

2022-03-29 00:00:00

Certain Stock Options of Geron Corporation are subject to a Lock-Up Agreement Ending on 28-JUN-2022. These Stock Options will be under lockup for 91 days starting from 29-MAR-2022 to 28-JUN-2022. Details: All of the officers and directors have agreed, subject to certain exceptions, not to (1) directly or indirectly (i) offer, pledge, sell, or contract to sell; (ii) sell any option or contract to purchase or purchase any option or contract to sell; (iii) grant any option, right or warrant for the sale; or (iv) dispose of or transfer any shares; or (2) otherwise enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of shares of our common stock or any securities convertible into or exchangeable or exercisable for shares of our common stock, whether now owned or acquired hereafter, without the prior written consent of Stifel, Nicolaus & Company, Incorporated, for a period of 90 days after the date of this prospectus supplement.

Negative

Certain Warrants of Geron Corporation are subject to a Lock-Up Agreement Ending on 28-JUN-2022.

2022-03-29 00:00:00

Certain Warrants of Geron Corporation are subject to a Lock-Up Agreement Ending on 28-JUN-2022. These Warrants will be under lockup for 91 days starting from 29-MAR-2022 to 28-JUN-2022. Details: All of the officers and directors have agreed, subject to certain exceptions, not to (1) directly or indirectly (i) offer, pledge, sell, or contract to sell; (ii) sell any option or contract to purchase or purchase any option or contract to sell; (iii) grant any option, right or warrant for the sale; or (iv) dispose of or transfer any shares; or (2) otherwise enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of shares of our common stock or any securities convertible into or exchangeable or exercisable for shares of our common stock, whether now owned or acquired hereafter, without the prior written consent of Stifel, Nicolaus & Company, Incorporated, for a period of 90 days after the date of this prospectus supplement.

Neutral

Geron Corporation - Shareholder/Analyst Call

2022-03-22 21:16:00

Annual Meeting of Stockholders

Neutral

Geron Corporation, Annual General Meeting, May 10, 2022

2022-03-22 21:16:00

Geron Corporation, Annual General Meeting, May 10, 2022, at 16:00 Pacific Standard Time. Agenda: To consider election of the two nominees for director named in the accompanying proxy statement to hold office as Class II members of the Board of Directors until the 2025 annual meeting of stockholders; to consider amendment to 2018 Equity Incentive Plan to increase the total number of shares of common stock issuable thereunder by 11,000,000 shares; to consider amendment to 2014 Employee Stock Purchase Plan to increase the number of shares of common stock issuable thereunder by 1,000,000 shares; to consider advisory vote to approve named executive officer compensation; and to consider ratification of Ernst & Young LLP as independent registered public accounting firm.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Neutral

Geron Corporation Presents at B. Riley Securities Oncology Investor Conference 2022, Jan-28-2022 11:00 AM

2022-01-21 12:30:00

Geron Corporation Presents at B. Riley Securities Oncology Investor Conference 2022, Jan-28-2022 11:00 AM. Speakers: Aleksandra Rizo, Executive VP & Chief Medical Officer, Anil Kapur, Chief Commercial Officer & Executive VP of Corporate Strategy, John A. Scarlett, CEO, President & Chairman of the Board, Olivia Kyusuk Bloom, Executive VP of Finance, CFO & Treasurer.

Negative

Geron Corporation Announces Executive Changes

2021-12-02 12:30:00

Geron Corporation announced the appointment of Edward Koval as Executive Vice President and Chief Business Officer. In his role at Geron, Mr. Koval will be a member of the Company’s Executive Management Committee and report to Dr. Scarlett. Mr. Koval will be responsible for business development, including evaluation and execution of out-licensing, in-licensing and strategic transaction opportunities. In connection with Mr. Koval’s appointment as Chief Business Officer, Melissa Kelly Behrs has been appointed Executive Vice President, Business Operations, and Chief Alliance Officer, and will continue to serve on the Executive Management Committee and report to Dr. Scarlett. Mr. Koval brings more than 25 years of biotech and pharmaceutical experience in business development and both in-licensing and out-licensing of products and platform technologies. Prior to joining Geron, Mr. Koval was the Chief Business Officer of ZebiAI Therapeutics.

Neutral

Geron Corporation Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 02:40 PM

2021-11-12 12:30:00

Geron Corporation Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 02:40 PM. Venue: New York, New York, United States. Speakers: John A. Scarlett, CEO, President & Chairman of the Board.

Positive

Geron Enters New Innovative Licensing and Access Pathway in the United Kingdom for Imetelstat

2021-10-25 20:30:00

Geron Corporation announced that imetelstat, the Company’s first in class telomerase inhibitor, has been granted an Innovation Passport, which is the first prescribed entry point to the Innovative Licensing and Access Pathway (ILAP) launched in the United Kingdom (UK) by the Medicines and Healthcare products Regulatory Agency (MHRA) in January 2021, post-Brexit. The objective of this new licensing and access pathway is to reduce the time to market for innovative medicines. Key benefits of being within ILAP include a 150-day accelerated assessment and rolling review of a Marketing Authorization Application (MAA), as well as opportunities for frequent interactions with the review staff at the MHRA and its partner agencies, including the National Institute for Health and Care Excellence (NICE), to discuss imetelstat’s development, regulatory plans and reimbursement plans. Patients from the IMerge Phase 2 clinical trial achieved durable transfusion independence with imetelstat treatment, including transfusion-free periods greater than one year, irrespective of the disease subgroup, such as ringed sideroblast positive or ringed sideroblast negative. Such durability provides significant and meaningful clinical benefit to lower risk MDS patients given their chronic anemia and the debilitating impact of serial blood transfusions. In addition, depletion of cytogenetic abnormalities and reductions in key driver mutations associated with lower risk MDS were observed, and these results were also correlated with transfusion independence. Taken together, the durability, molecular and cytogenetic data from IMerge Phase 2 provide strong evidence for disease-modifying activity of imetelstat which has the potential to differentiate it from other currently approved and investigational treatments in lower risk MDS today. Imetelstat is currently being studied in two Phase 3 clinical trials, IMerge Phase 3 in lower risk MDS and IMpactMF in refractory myelofibrosis. Based upon current planning assumptions, Geron expects top-line results for the IMerge Phase 3 clinical trial to be available at the beginning of January 2023.

Positive

Geron Announces Completion of Patient Enrollment in Imerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

2021-10-18 11:30:00

Geron Corporation announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). Based upon current planning assumptions, Geron expects top-line results for IMerge Phase 3 to be available at the beginning of January 2023. Patients from the IMerge Phase 2 clinical trial achieved durable transfusion independence with imetelstat treatment, including transfusion-free periods greater than one year, irrespective of the disease subgroup, such as ringed sideroblast positive or ringed sideroblast negative. Such durability provides significant and meaningful clinical benefit to lower risk MDS patients given their chronic anemia and the debilitating impact of serial blood transfusions. In addition, depletion of cytogenetic abnormalities and reductions in key driver mutations associated with lower risk MDS were observed, and these results were also correlated with transfusion independence. Based on the IMerge Phase 2 data, taken together, the durability, molecular and cytogenetic data provide strong evidence for disease-modifying activity of imetelstat, which has the potential to differentiate it from other currently approved and investigational treatments in lower risk MDS.

Neutral

Geron Corporation - Special Call

2021-10-15 20:05:00

To discuss The unmet medical needs in lower risk myelodysplastic syndromes and refractory myelofibrosis and the disease modification potential of imetelstat, Geron’s first-in-class telomerase inhibitor; and to consider Expansion opportunities for imetelstat into new indications and in combination with other drugs

Positive

Geron Corporation Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology

2021-10-11 20:30:00

Geron Corporation announced the publication in the Annals of Hematology of a paper entitled “Favorable Overall Survival with Imetelstat in Relapsed/Refractory Myelofibrosis Patients Compared with Real World Data,” which details statistical analyses comparing data from the Company’s IMbark Phase 2 clinical trial to closely matched Real World Data (RWD). The paper describes several statistical adjustment methods and multiple sensitivity analyses to improve comparability of the data set from the Company’s IMbark Phase 2 trial and RWD to mimic the effect of a randomized trial. The authors note consistency in the hazard ratios and statistical significance observed across the multiple analyses, which suggests a survival benefit associated with imetelstat treatment of MF patients after ruxolitinib failure. While acknowledging the limitations of RWD analyses, the authors conclude that the results of these analyses warrant further prospective evaluation of imetelstat in a Phase 3 setting with OS as a primary endpoint. IMpactMF is an open label, randomized, controlled Phase 3 clinical trial with registrational intent. The trial is designed to enroll approximately 320 patients with Intermediate-2 or High-risk myelofibrosis who are refractory to prior treatment with a JAK inhibitor, also referred to as refractory MF. Patients will be randomized to receive either imetelstat or best available therapy. The primary endpoint is overall survival (OS). Key secondary endpoints include symptom response, spleen response, progression free survival, complete response, partial response, clinical improvement, duration of response, safety, pharmacokinetics, and patient reported outcomes. IMpactMF is currently enrolling patients.

Neutral

Geron Corporation Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-09-01 20:30:00

Geron Corporation Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: John A. Scarlett, CEO, President & Chairman of the Board.

Neutral

Geron Corporation Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 03:20 PM

2021-09-01 20:30:00

Geron Corporation Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 03:20 PM. Venue: New York, United States.

Neutral

Geron Corporation Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 02:00 PM

2021-08-26 17:20:00

Geron Corporation Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 02:00 PM. Speakers: John A. Scarlett, CEO, President & Chairman of the Board.

Positive

Geron Corporation Reports Greater Than 90% Enrollment in Imerge Phase 3 and Expected Top-Line Results Accelerated to First Quarter of 2023

2021-08-16 20:06:00

Geron Corporation reported updates on the IMerge Phase 3 trial in lower risk MDS and financial results for the second quarter ended June 30, 2021. The Company will host a conference call at 4:30 p.m. ET to discuss these updates and current events. As of June 30, 2021, the Company had $239.1 million in cash and marketable securities. These financial resources, combined with expected future non-dilutive funding under the current debt facility, are expected to fund operations through the end of the first quarter of 2023.

Neutral

Geron Corporation has filed a Shelf Registration in the amount of $22.326 million.

2021-08-16 00:00:00

Geron Corporation has filed a Shelf Registration in the amount of $22.326 million. Security Name: Common Stock Securities Offered: 18,300,000 Transaction Features: ESOP Related Offering

Neutral

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Neutral

Geron Corporation, Q2 2021 Earnings Call, Aug 16, 2021

2021-08-05 20:30:00

Geron Corporation, Q2 2021 Earnings Call, Aug 16, 2021

Neutral

Geron Corporation to Report Q2, 2021 Results on Aug 16, 2021

2021-08-05 20:30:00

Geron Corporation announced that they will report Q2, 2021 results After-Market on Aug 16, 2021

Neutral

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.

Fundamental Summary

Geron's financial results from Q1 demonstrated decent performance, but will likely only help Geron remain on par with its peers. This typically translates into the stock performing on par with market performance for the upcoming quarter. Overall, Geron's growth and income factors are trending positively, and we, therefore, give Geron an overall grade of 70 and a HOLD recommendation.

Geron reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 30.1 million compared to USD 27.82 million a year ago. Basic loss per share from continuing operations was USD 0.09 compared to USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.09 compared to USD 0.09 a year ago.

Business Description

Geron, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Sector Overview

Geron is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Geron's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 198.4 -12.2% 72
Liabilities 100.9 1.3% 69
Price to Book 4.2 32.9% 62
Cash & Equivalents 31.3 -10.2% 59
Equity 97.5 -22.9% 37
EBITDA -112.9 -0.2% 67
Total Revenues 1.4 -1.0% 89
Parameter Value Change Score
Return on Equity -79.3 -15.2% 73
Net Cashflow -0.2 -100.8% 78
Capital Expenditure -0.2 -19.3% 49
Asset Turnover 0.0 7.6% 81
Free Cashflow -0.3 -0.7% 68

* All values are TTM

The below chart reflects Geron's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Geron's peer average final assessment score stands on 64.0, Geron's score is 70.

  •  GERN
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 26 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 28 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 30 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 31 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 32 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 33 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 36 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 37 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 38 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Geron's stock is now priced above its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the near, medium, and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Geron's stock indicates that it's likely oversold. Overall, these technical indicators signal positive upward momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 78.

Bullish 78
Close Price 1.5
52W Low 0.99
52W High 1.72
5D MA 1.39
50D MA 1.38
200D MA 1.32
MACD 0.01
RSI 0.05
STOCH 100.0

Balance Sheet Analysis

Overall, Geron's critical balance sheet metrics appear to signal strong support and a high likelihood of positive growth going forward. Geron assets on their balance sheet, moved to 198.4, which is a -12.2% change from the last period. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Therefore, its asset component earned a score of 72. Also, Geron is doing a good job of keeping its liabilities under control and growing intelligently. At filing, their liabilities were 100.9, representing 1.3% change from the previous period. This performance is all interesting relative to their peers and suggests that their stock price has room to grow to reflect a higher intrinsic value. The company's liabilities movement component, therefore, received a grade of 69. That said, one metric, Equity, stood out as particularly concerning. Geron published concerning equity metrics for this filing. In the current report, equity stood at 97.5, which represents a -22.9% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. This performance is significantly less impressive than its peers and competitors. Consequently, their equity movement received a grade of 37. Because its management is doing an excellent job managing these critical metrics, the balance sheet was given a score of 60.

Parameter Value Change Score
Assets 198.4 -12.2% 72
Liabilities 100.9 1.3% 69
Price to Book 4.2 32.9% 62
Cash & Equivalents 31.3 -10.2% 59
Equity 97.5 -22.9% 37
* All values are TTM

The below chart describes Geron's performance as reflected on its balance sheet with respect to its peers. While Geron received a balance sheet score of 60, the average of its peers stands on 62.0.

  •  GERN
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 26 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 28 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 30 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 31 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 32 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 33 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 34 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 36 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 37 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 38 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Overall, Geron's critical income statement metrics appear to signal strong support and a high likelihood of positive growth going forward. Geron's financials reveal an interesting trend for their revenue efficiency. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their industry-leading revenue efficiency makes a strong case for upward pressure on its's stock price. Consequently, their revenue efficiency received a grade of 89. Also, Return factors metrics and ratios were exceptional in this report. Geron reported a return on equity (ROE) ratio of -79.3, representing a change of -15.2% from the last report. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Consequently, their return factors received a grade of 73. On the other hand, EBITDA, jumped out as looking problematic. Geron's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -112.9, which represents a -0.2% change from the last period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Its EBITDA movement, therefore, received a grade of 67. Its income statement, therefore, earned a score of 78.

Parameter Value Change Score
EBITDA -112.9 -0.2% 67
Total Revenues 1.4 -1.0% 89
Return on Equity -79.3 -15.2% 73
* All values are TTM

The below chart describes Geron's performance as reflected on its income statement with respect to its peers. While Geron received a income statement score of 78 , the average of its peers stands on 67.0.

  •  GERN
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 26 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 28 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 29 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 30 1
IVERIC bio, Inc. 1.1B 84 58 79 70 31 1
FibroGen, Inc. 1.0B 48 74 63 67 32 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 33 1
ImmunoGen, Inc. 946.1M 40 73 71 64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 36 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 37 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 38 1
AnaptysBio, Inc. 586.3M 97 50 77 68 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Two main cash flow metrics, Asset Turnover and Net Cash Flow, are driving the positive outlook for Geron's financial strength. Geron is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.0, representing a 7.6% change from the previous period. This metric might have a 4.1 percent impact on companies in the same industry and with the same market capitalization. Their asset turnover numbers are significantly more impressive when contrasted against their peers and competitors. Therefore, its asset turnover movement earned a score of 81. Also, Geron presents exciting net cash flow numbers for its recent financial release, illustrated by a net cash flow of -0.2, which is a change of -100.8% from the last filing. This industry-leading net cash flow momentum should reinforce broader positive momentum for its's stock price going forward. Hence, its net cash flow earned a score of 78. At the same time, one critical cash flow metric, Capital Expenditure, was notably weak. Geron's published capital expenditures (CapEx) numbers were discouraging and reflected management's unbalanced growth strategy. Geron recorded CapEx of -0.2, which represents a -19.3% change from the previous report. The company's disappointing CapEx growth is expected to stunt the momentum they hoped for this period. Consequently, their CapEx movement received a grade of 49. Therefore, we scored the company's cash flow a 77.

Parameter Value Change Score
Net Cashflow -0.2 -100.8% 78
Capital Expenditure -0.2 -19.3% 49
Asset Turnover 0.0 7.6% 81
Free Cashflow -0.3 -0.7% 68
* All values are TTM

The below chart describes Geron's performance as reflected on its cash flow with respect to its peers. While Geron received a cash flow score of 77, the average of its peers stands on 69.0.

  •  GERN
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 26 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 28 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 29 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 30 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 31 1
FibroGen, Inc. 1.0B 86 74 48 87 84 32 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 33 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 34 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 36 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 37 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 38 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.